Roivant Sciences Ltd.
ROIV
$10.66
$0.242.30%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | 113.56M | 5.04B | 5.04B | 4.65B | 4.80B |
Total Depreciation and Amortization | 12.05M | 12.63M | 12.63M | 13.58M | 8.36M |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -516.00M | -5.52B | -5.52B | -5.23B | -5.25B |
Change in Net Operating Assets | -118.15M | -43.85M | -43.85M | -7.52M | -23.47M |
Cash from Operations | -508.54M | -511.74M | -708.17M | -765.27M | -835.90M |
Capital Expenditure | -3.14M | -1.67M | -1.67M | -1.11M | -758.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | 153.63M | 5.23B | 5.23B | 5.23B | 5.23B |
Other Investing Activities | 309.55M | 8.08M | 8.08M | 8.59M | 508.00K |
Cash from Investing | 460.04M | 5.24B | 5.20B | 5.20B | 5.31B |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -58.59M | -17.16M | -17.16M | -23.14M | -15.47M |
Issuance of Common Stock | 34.04M | 14.81M | 14.81M | 33.56M | 29.91M |
Repurchase of Common Stock | -941.65M | -692.99M | -692.99M | -37.67M | -9.06M |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 0.00 | 238.73M | 238.73M | 238.73M | 238.73M |
Cash from Financing | -966.19M | -456.60M | -248.73M | 419.36M | 662.32M |
Foreign Exchange rate Adjustments | -4.66M | -553.00K | -553.00K | 2.07M | 2.93M |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -1.02B | 4.27B | 4.24B | 4.86B | 5.14B |